ABPI analyzes the impacts of NICE’s evaluation changes for pharma and patients

The Association of the British Pharmaceutical Industry (ABPI; London, UK) has published comments on new guidance from NICE (London, UK), which aims to increase the flexibility of medicine evaluations and health technology assessments. In particular, the association focused their comments on how changes could impact the pharma industry and patients. Initial comments from the ABPI praised the flexibility and pragmatism of the new guidance in providing improved opportunities for patient access. The modular approach adopted by NICE to improve progress in medicine access was also noted as beneficial to stakeholders.  However, the analysis of the evaluation changes recommended some aspects...